Yayın:
Investigation Of Structure-Activity Relationships With Molecular Docking For Some Antiepileptic Drugs And Voltage-Gated Calcium (CaV) Channels

dc.contributor.authorÇakmak, Esra Nur
dc.contributor.authorGür, Mahmut
dc.contributor.authorKiran, Bayram
dc.date.accessioned2026-01-04T16:53:41Z
dc.date.issued2022-06-09
dc.description.abstractIn the study, the active drugs molecules used in the treatment of convulsive seizures occurring in epilepsy disease were used. These molecules; Vigabatrin, Lokosamidin, Zonisamide, Oxcarbazepine, Levetiracetam, Tiagabin, Topiramate, Lamotrigine, Gabapentin, Felbamate, Ethosuximide, Valproic Acid, Mesuximide, Ethotoin, Primidone, Trimethadion, Phenytoin, Remasemide, Mephenytoin. These molecules have been selected considering the physiopathological mechanisms of action of epilepsy. Since the selected molecules are used as a potential antiepileptic agent, they were deemed suitable for molecular insertion studies. In addition, voltage-gated calcium channels, which play an important role in epilepsy, are emphasized. Voltage-gated calcium channels (CaV) act by providing the flow of Ca+ ions during the action potential that triggers seizure formation, and among the ten subtypes of voltage-gated calcium (CaV) channels, CaV3.1- CaV3.3, T-type or abnormal activities are associated with epilepsy, psychiatric form the associated low-voltage-activated subfamily. For this reason, the PDB ID: 6KZP receptor, which acts as an antagonist according to its activity on the channel in the formation of epileptic seizures, was chosen for the molecular insertion study. As a result of molecular placement studies; Oxcarbazepine and Phenytoin gave the best binding affinity for 6KZP with a value of -7.5 kcal/mol. Other results are in descending order (in kcal/mol); Tiagabine (-7.4), Mesuximide (-7.3), Primidone (-7.1), Remasemide (-7.0), Topiramate (-6.9) Mephenytoin (-6.7), Lomotrigine and Ethotoin (-6.4), Locosamide and Zonisamide (-6.1) , Felbamate (-6.0), Levetiracetam and Gabapentin (-5.4), Esuximide (-5.1), Valproic Acid (-4.9), Trimethadione (-4.7), Vigabatrin (-4.4) determined as.
dc.description.urihttps://doi.org/10.55385/kastamonujes.1094129
dc.description.urihttps://dergipark.org.tr/tr/pub/kastamonujes/issue/70574/1094129
dc.identifier.doi10.55385/kastamonujes.1094129
dc.identifier.eissn2667-8209
dc.identifier.openairedoi_dedup___::4e71e20be08485ee301e64440116da6f
dc.identifier.urihttps://hdl.handle.net/20.500.12597/39753
dc.language.isoeng
dc.publisherKastamonu University
dc.relation.ispartofKastamonu University Journal of Engineering and Sciences
dc.subjectEngineering
dc.subjectMühendislik
dc.subjectCalcium Channels
dc.subjectEpilepsy
dc.subjectMoleculer Docking
dc.subjectLigand
dc.subjectReceptor
dc.subjectDrug
dc.subject.sdg3. Good health
dc.titleInvestigation Of Structure-Activity Relationships With Molecular Docking For Some Antiepileptic Drugs And Voltage-Gated Calcium (CaV) Channels
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"ÇAKMAK, Esra Nur","name":"Esra Nur","surname":"Çakmak","rank":1,"pid":null},{"fullName":"GÜR, Mahmut","name":"Mahmut","surname":"Gür","rank":2,"pid":null},{"fullName":"KIRAN, Bayram","name":"Bayram","surname":"Kiran","rank":3,"pid":null}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Engineering"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Mühendislik"},"provenance":null},{"subject":{"scheme":"keyword","value":"Calcium Channels;Epilepsy;Moleculer Docking;Ligand;Receptor;Drug"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Investigation Of Structure-Activity Relationships With Molecular Docking For Some Antiepileptic Drugs And Voltage-Gated Calcium (CaV) Channels","subTitle":null,"descriptions":["<jats:p xml:lang=\"en\">In the study, the active drugs molecules used in the treatment of convulsive seizures occurring in epilepsy disease were used. These molecules; Vigabatrin, Lokosamidin, Zonisamide, Oxcarbazepine, Levetiracetam, Tiagabin, Topiramate, Lamotrigine, Gabapentin, Felbamate, Ethosuximide, Valproic Acid, Mesuximide, Ethotoin, Primidone, Trimethadion, Phenytoin, Remasemide, Mephenytoin. These molecules have been selected considering the physiopathological mechanisms of action of epilepsy. Since the selected molecules are used as a potential antiepileptic agent, they were deemed suitable for molecular insertion studies. In addition, voltage-gated calcium channels, which play an important role in epilepsy, are emphasized. Voltage-gated calcium channels (CaV) act by providing the flow of Ca+ ions during the action potential that triggers seizure formation, and among the ten subtypes of voltage-gated calcium (CaV) channels, CaV3.1- CaV3.3, T-type or abnormal activities are associated with epilepsy, psychiatric form the associated low-voltage-activated subfamily. For this reason, the PDB ID: 6KZP receptor, which acts as an antagonist according to its activity on the channel in the formation of epileptic seizures, was chosen for the molecular insertion study. As a result of molecular placement studies; Oxcarbazepine and Phenytoin gave the best binding affinity for 6KZP with a value of -7.5 kcal/mol. Other results are in descending order (in kcal/mol); Tiagabine (-7.4), Mesuximide (-7.3), Primidone (-7.1), Remasemide (-7.0), Topiramate (-6.9) Mephenytoin (-6.7), Lomotrigine and Ethotoin (-6.4), Locosamide and Zonisamide (-6.1) , Felbamate (-6.0), Levetiracetam and Gabapentin (-5.4), Esuximide (-5.1), Valproic Acid (-4.9), Trimethadione (-4.7), Vigabatrin (-4.4) determined as.</jats:p>"],"publicationDate":"2022-06-09","publisher":"Kastamonu University","embargoEndDate":null,"sources":["Crossref","Volume: 8, Issue: 1 28-53","2667-8209","Kastamonu University Journal of Engineering and Sciences","Kastamonu Üniversitesi Mühendislik ve Fen Bilimleri Dergisi"],"formats":["application/pdf"],"contributors":null,"coverages":null,"bestAccessRight":null,"container":{"name":"Kastamonu University Journal of Engineering and Sciences","issnPrinted":null,"issnOnline":"2667-8209","issnLinking":null,"ep":null,"iss":null,"sp":null,"vol":null,"edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::4e71e20be08485ee301e64440116da6f","originalIds":["10.55385/kastamonujes.1094129","50|doiboost____|4e71e20be08485ee301e64440116da6f","oai:dergipark.org.tr:article/1094129","50|tubitakulakb::728fca6e7b2b443416a5231a13fcc175"],"pids":[{"scheme":"doi","value":"10.55385/kastamonujes.1094129"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0,"influence":2.5349236e-9,"popularity":1.8548826e-9,"impulse":0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"instances":[{"pids":[{"scheme":"doi","value":"10.55385/kastamonujes.1094129"}],"type":"Article","urls":["https://doi.org/10.55385/kastamonujes.1094129"],"publicationDate":"2022-06-09","refereed":"peerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.55385/kastamonujes.1094129"}],"type":"Article","urls":["https://dergipark.org.tr/tr/pub/kastamonujes/issue/70574/1094129"],"publicationDate":"2022-03-27","refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire

Dosyalar

Koleksiyonlar